Hilde Furberg

Biography

Mrs. Hilde Furberg, MSc serves as Senior Vice President Rare Disease EMEA at Genzyme (Sanofi). Mrs. Furberg has been Vice President and General Manager of Nordic/Benelux Genzyme since 2006. She joined Genzyme (Sanofi) in 2002. She has been Senior Vice President at PGH (Personalized Genetic Health) since 2010. She has been General Manager of Genzyme A/S since 2002. Mrs. Furberg served as the Managing Director and Part-Owner of Pharmalink, Denmark from 1998 to 2002. She served at Baxter from 1996 to 1998. She has 30 years of experience in the pharmaceutical industry. She served as Chairman of BerGenBio AS from February 2016 to January 26, 2017. She served as Chairman of the Board at Pharmalink AB from December 26, 2016 to January 2017. She has been Vice Chairman of the Board at Pharmalink AB since January 2017. She has been a Non-Executive Director of BerGenBio AS since June 22, 2015 and Pharmalink AB since July 2014. Mrs. Furberg has been a Director of Copenhagen Capacity A/S since 2007 and Algeta ASA since April 2013. She served as a Director of Weifa ASA and Clavis Pharma ASA. She served as a Director of Probi AB from 2005 to April 2011 and Pronova BioPharma ASA since May 2011. She served as a Director of Aqualis ASA. She has a B.Sc. in Medical Technology and a Master of Science degree in Nuclear Analytical Chemistry from University of Oslo.

Research Interest

Rare Disease